SEATTLE--(BUSINESS WIRE)--Cadence BiomedicalTM, maker of the Kickstart® which helps people with neurological conditions recover to walking, today announced that its research collaborators from the Université de Montréal and the Center for Interdisciplinary Research in Rehabilitation of Greater Montreal have secured a grant from the Physiotherapy Foundation of Canada and the Quebec Rehabilitation Research Network. The grant will be used to study the effects of Kickstart with stroke survivors.
Dr. Dany Gagnon of the Université de Montréal is the principal investigator on the grant entitled “Effects of a novel elasticity-based lower limb assistive exoskeleton on walking and walking-related abilities in individuals with post-stroke hemiparesis and users’ satisfaction,” and will lead a team of collaborators from his institution and McGill University. Cadence COO Brian Glaister will serve as a co-investigator on this grant.
“A stroke occurs in Canada every 10 minutes and stroke is costing the Canadian economy over $3.6 billion in medical costs and lost productivity,” said Dany Gagnon, Ph.D., PT. “At Université de Montréal we are very interested in studying mobility assistive technologies such as Kickstart. The end goal is to help patients accelerate their recovery and reduce healthcare costs while improving the quality of life for stroke survivors.”
“Stroke is a rapidly-growing global concern. We are very grateful to be working with Dr. Gagnon and his world-renowned research team to further investigate Kickstart’s ability to help stroke survivors recover to walking,” said Cadence COO Brian Glaister. “This study adds to a set of growing independent research that confirms that Kickstart can make an early and meaningful difference in the gait of stroke survivors.”
About Cadence Biomedical
Cadence Biomedical, headquartered in Seattle, Washington, is a commercial-stage medical device company that is committed to helping people with neurological impairments retrain the ability to walk and regain their lives. Cadence develops and markets the Kickstart Walking System, first in a new class of orthotic devices which provides stability and movement assistance to weakened muscles without the use of powered mechanisms. The company recently announced the close of a $1.2M Series B investment round, led by HealthTech Capital and included participation from BioPacific Investments, Frontier Angel Fund and individual investors. For more information, please visit www.cadencebiomedical.com, www.twitter.com/cadencebio, and www.facebook.com/kickstartwalking.
